Tirzepatide Research: What Happened in Each Study
What can Tirzepatide research tell you?
Made as a weekly shot, tirzepatide is a peptide, meaning a short chain of protein parts, and this page follows the work from 2018 cell and mouse tests through the large Phase 3 human trials. The trials here cover type 2 diabetes, weight, sleep apnea, heart failure, and severe fatty liver disease.
Each year and result comes from the paper named here. Cells, mice, and people answer different questions. Each result says who or what was tested. You can then see how much trust the finding deserves.
What did researchers learn from 2018 through 2022?
In 2018, Coskun and his team wrote the first main tirzepatide paper, reporting that the drug acted in cells like two gut hormones known by the short names GIP and GLP-1 [1]. Both help control blood sugar after food. In mice, tirzepatide lowered sugar, food intake, and weight more than a drug that copied GLP-1 alone [1]. Mice can't prove what will happen to a person. A Phase 1 study, an early test in 142 people, found that the drug lasted long enough for one shot a week [1].
A 2020 cell study came from Willard and his team [2]. Cells responded more strongly to GIP than to GLP-1. They also stayed ready to release insulin for longer. In groups of insulin-making cells, tirzepatide avoided a change that made the GLP-1 response fade [2].
In 2021, Novikoff and his team watched living cells [4]. The cells stayed ready to release insulin, though only part of the usual cell response occurred. The parts that sense GLP-1 also remained at the cell surface longer [4]. In 2022, Sun and his team used a powerful microscope. They saw how tirzepatide grips the cell parts that sense both hormones [7]. Gripping both cell parts may explain how one drug copies both hormones. The microscope image can't predict your benefit or risk.
In 2024, Douros and his team reviewed those cell tests [9]. They thought the longer response might help explain more insulin release and weight loss. Repeated cell work supports that idea, but the work still isn't proof in a person. Only human trials show what happened after people received the drug. Every result in these early papers came from cells, so each remains a lab finding.
What changed for people with type 2 diabetes?
In 2021, SURPASS-1 found larger drops in weight and the three-month blood sugar result as doses rose among people with type 2 diabetes who used tirzepatide or received placebo, a shot without tirzepatide [11]. Also in 2021, SURPASS-3 compared two add-on treatments for type 2 diabetes. Tirzepatide lowered blood sugar and weight more than daily long-acting insulin degludec. Both groups also took metformin, a common diabetes pill [12].
In 2021, the Phase 3 SURPASS-2 trial directly compared weekly shots in 1,879 adults with type 2 diabetes [3]. At 5, 10, and 15 mg, tirzepatide lowered the three-month blood sugar result by 2.01, 2.24, and 2.30 points. Semaglutide 1 mg, another weekly diabetes shot, lowered it by 1.86 points. Each tirzepatide dose produced a larger drop [3]. People also lost 1.9, 3.6, and 5.5 kg more weight [3].
In 2025, researchers reviewed several SURPASS trials in type 2 diabetes. They counted 3,676 people for blood sugar and 4,121 for weight. A sugar drop of at least 20% by week 4 often came before better results on the three-month blood sugar test. People without that early drop still improved at every dose [10]. Among adults aged 65 years or more with BMI below 30, meaning a lower doctor-used height-and-weight number, the three-month sugar result fell 1.97% to 2.10%. Very low blood sugar didn't rise [36].
What did Tirzepatide vs semaglutide change on the scale?
In 2025, SURMOUNT-5 compared the shots for 72 weeks in 751 adults. They had obesity but no type 2 diabetes [6]. Tirzepatide doses were 10 or 15 mg. Semaglutide doses were 1.7 or 2.4 mg. Average weight fell 20.2% with tirzepatide and 13.7% with semaglutide. The study found a clear gap [6]. More tirzepatide users reached one of the study's four weight-loss goals, written as 10/15/20/25% of starting weight [6]. Each higher goal meant a larger loss. These are group averages, not a promise for you. Because both drugs were tested under the same rules, the study gives a fair comparison.
What did Tirzepatide weight loss trials find?
In 2022, the 72-week SURMOUNT-1 Phase 3 trial, a large late test used before approval, followed 2,539 adults who had obesity but did not have diabetes [5]. Average weight fell 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg. People given placebo, a shot with no tirzepatide, lost 3.1%. Most harms were mild or moderate stomach and bowel problems. They were worst while doses went up [5].
In 2023, SURMOUNT-2 included adults with obesity and type 2 diabetes. The 10 and 15 mg groups lost much more weight than the placebo group [37]. In 2024, everyone in SURMOUNT-4 first took tirzepatide during a 36-week first stage. Average weight fell 20.9%. At week 88, those who stayed on it lost another 5.5%. People moved to placebo regained 14.0% [30].
In 2025, a follow-up reported the final 2025 SURMOUNT-1 results for adults with obesity and prediabetes. Their weight loss held, and fewer developed type 2 diabetes [38]. These are averages from set groups. Your weight may change by less, more, or not at all.
What changed in sleep, heart, and liver trials?
In 2024, SURMOUNT-OSA followed adults with obesity and serious sleep apnea for 52 weeks [13]. Breathing pauses fell by 25.3 each hour without a mask machine. They fell by 29.3 each hour among people who used a mask machine that pushes air while they sleep. Placebo cut about 5 pauses each hour [13]. This finding backed FDA clearance for sleep apnea.
In 2025, SUMMIT studied adults with obesity and heart failure [14]. Their hearts could squeeze well but didn't fill as they should. Tirzepatide users had fewer bouts of worsening heart failure. They also walked farther and handled daily tasks better than people given placebo [14]. A 2024 meeting paper summed up this result and the sleep trial. It didn't test new people or add a new finding [39].
In 2024, SYNERGY-NASH studied adults with severe fatty liver disease and moderate-to-serious liver scars [35]. The disease cleared more often with tirzepatide than with placebo. Liver scars didn't get worse [35].
What do Tirzepatide reviews add?
In 2025, two 2025 papers from Samms and his team reviewed past work on the drug's two gut-hormone actions [40][9]. They proposed that the action tied to GIP may curb hunger and help fat cells handle blood fats. Those ideas might explain some effects beyond the other gut-hormone action. A 2024 doctor's handbook also listed the cleared uses and explained how the shot works [22]. Reviews don't test new people. Your health may differ from the people in any trial.
Which harms appeared in Tirzepatide trials?
In 2023, Mishra and his team reviewed human trials [18]. Nausea, vomiting, loose stools, and low hunger grew more common as doses rose. In 2025, a later safety review found nausea in 27.7% of reports and loose stools in 12.8%. The middle start time was 16 days, and most cases began within 3 months [19]. Those are shares of reports, not shares of all users.
In 2023, Zeng and his team combined nine trials with 9,871 people. They didn't find a clear rise in pancreatitis, which is a swollen and painful pancreas. The authors couldn't be 95% sure that risk rose, so the review didn't settle the question. Gallbladder or bile-duct trouble was 1.97 times as likely as with other care. They were 95% sure that rise wasn't due to chance [15].
In 2025, a SURMOUNT-1 scan study found that about 25% of lost weight was muscle and other tissue that wasn't fat. About 75% was fat [23]. In 2026, a wider review found 28% as the middle result: half of its findings were lower, and half were higher [25].
The papers appear under Tirzepatide references. You can take these figures to your doctor.